Aura Biosciences (AURA) Competitors $8.95 -0.08 (-0.89%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AURA vs. UROV, PRQR, URGN, PSNL, IVA, GLPG, ARVN, XNCR, RXRX, and IMCRShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Urovant Sciences (UROV), ProQR Therapeutics (PRQR), UroGen Pharma (URGN), Personalis (PSNL), Inventiva (IVA), Galapagos (GLPG), Arvinas (ARVN), Xencor (XNCR), Recursion Pharmaceuticals (RXRX), and Immunocore (IMCR). These companies are all part of the "medical" sector. Aura Biosciences vs. Urovant Sciences ProQR Therapeutics UroGen Pharma Personalis Inventiva Galapagos Arvinas Xencor Recursion Pharmaceuticals Immunocore Aura Biosciences (NASDAQ:AURA) and Urovant Sciences (NASDAQ:UROV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk. Which has more volatility and risk, AURA or UROV? Aura Biosciences has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Is AURA or UROV more profitable? Urovant Sciences' return on equity of 0.00% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -41.57% -36.43% Urovant Sciences N/A N/A -162.90% Does the MarketBeat Community believe in AURA or UROV? Urovant Sciences received 55 more outperform votes than Aura Biosciences when rated by MarketBeat users. However, 62.16% of users gave Aura Biosciences an outperform vote while only 57.35% of users gave Urovant Sciences an outperform vote. CompanyUnderperformOutperformAura BiosciencesOutperform Votes2362.16% Underperform Votes1437.84% Urovant SciencesOutperform Votes7857.35% Underperform Votes5842.65% Do insiders and institutionals believe in AURA or UROV? 96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are held by institutional investors. 5.4% of Aura Biosciences shares are held by company insiders. Comparatively, 2.7% of Urovant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend AURA or UROV? Aura Biosciences presently has a consensus price target of $23.00, indicating a potential upside of 156.98%. Given Aura Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Aura Biosciences is more favorable than Urovant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Urovant Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation and earnings, AURA or UROV? Aura Biosciences is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$76.41M-$1.73-5.17Urovant SciencesN/AN/A-$146.74M-$4.71-3.45 Does the media refer more to AURA or UROV? In the previous week, Aura Biosciences had 13 more articles in the media than Urovant Sciences. MarketBeat recorded 13 mentions for Aura Biosciences and 0 mentions for Urovant Sciences. Aura Biosciences' average media sentiment score of 0.63 beat Urovant Sciences' score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media. Company Overall Sentiment Aura Biosciences Positive Urovant Sciences Neutral SummaryAura Biosciences beats Urovant Sciences on 12 of the 16 factors compared between the two stocks. Ad Chaikin Analytics50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$447.05M$3.04B$5.36B$8.84BDividend YieldN/A1.91%5.09%4.09%P/E Ratio-5.1742.67105.7117.69Price / SalesN/A352.381,240.48162.66Price / CashN/A169.3840.0036.29Price / Book2.564.597.076.50Net Income-$76.41M-$41.63M$119.18M$226.03M7 Day Performance-5.49%2.49%2.15%3.96%1 Month Performance-21.42%-3.47%-3.13%3.77%1 Year Performance12.16%28.34%33.60%29.32% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences3.5219 of 5 stars$8.95-0.9%$23.00+157.0%+12.2%$447.05MN/A-5.1750UROVUrovant SciencesN/A$16.24flatN/AN/A$531.75MN/A-3.4570PRQRProQR Therapeutics2.0955 of 5 stars$3.62+0.3%$7.13+96.8%+151.4%$295.68M$7.05M-11.31180News CoverageURGNUroGen Pharma3.743 of 5 stars$11.91+3.1%$48.38+306.2%-4.9%$279.34M$89.36M-3.69200PSNLPersonalis4.2098 of 5 stars$3.47+2.7%$6.81+96.3%+153.3%$245.15M$87.49M-2.07400IVAInventiva3.0477 of 5 stars$2.62-1.5%$13.25+406.7%-34.4%$137.24M$18.91M0.00100Analyst ForecastNews CoverageGap DownGLPGGalapagos1.2935 of 5 stars$27.13+7.6%$30.75+13.3%-26.7%$1.79B$260.09M0.001,123Analyst DowngradeGap UpARVNArvinas3.067 of 5 stars$25.86+3.0%$61.08+136.2%+20.8%$1.78B$161.10M-5.48445Analyst ForecastAnalyst RevisionNews CoverageGap UpXNCRXencor3.5938 of 5 stars$25.01+3.8%$35.75+42.9%+33.5%$1.75B$85.16M-7.55280RXRXRecursion Pharmaceuticals2.0565 of 5 stars$5.70-0.9%$9.25+62.3%-15.9%$1.63B$44.58M-3.73400Analyst ForecastOptions VolumeHigh Trading VolumeIMCRImmunocore2.8635 of 5 stars$32.28+0.5%$69.18+114.3%-29.3%$1.61B$249.43M-33.81497Positive News Related Companies and Tools Related Companies Urovant Sciences Competitors ProQR Therapeutics Competitors UroGen Pharma Competitors Personalis Competitors Inventiva Competitors Galapagos Competitors Arvinas Competitors Xencor Competitors Recursion Pharmaceuticals Competitors Immunocore Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AURA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AURA Stock Alerts